Clinical Trials Directory

Trials / Completed

CompletedNCT03382873

Augmented Care at Worksite for Diabetes Prevention

Impact of Augmented Care at the Worksite for Diabetes Prevention

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
208 (actual)
Sponsor
Ohio State University · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study was to evaluate the impact of augmented care at the worksite through a lifestyle intervention for diabetes prevention among employees with prediabetes who were slower to respond to a standard diabetes prevention intervention.

Detailed description

Employees at the Ohio State University (OSU) with prediabetes participated in a standard lifestyle intervention (Group Lifestyle Balance) for diabetes prevention. Participants who did not achieve \>2.5% weight loss at week 5 of the intervention were stratified to the augmented intervention (Group Lifestyle Balance Plus) at week 5. The impact of the augmented intervention compared to the standard intervention was determined at 4, 12 and 18 months from baseline to determine if implementing early enhanced training helped participants achieve and maintain weight loss similar to those who received the standard intervention.

Conditions

Interventions

TypeNameDescription
BEHAVIORALGroup Lifestyle Balance (GLB)The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.
BEHAVIORALGroup Lifestyle Balance Plus (GLB+)The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.

Timeline

Start date
2018-02-08
Primary completion
2022-04-15
Completion
2022-04-15
First posted
2017-12-26
Last updated
2024-04-11
Results posted
2024-04-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03382873. Inclusion in this directory is not an endorsement.